LAG3: The Biological Processes That Motivate Targeting This Immune Checkpoint Molecule in Human Cancer

Indoleamine Dioxygenase Inhibitors: Clinical Rationale and Current Development

(2019) Mayanne M. T. Zhu et al.   Current Oncology Reports

Roles, function and relevance of LAG3 in HIV infection

(2019) Colin G. Graydon et al.   PLoS Pathogens

A Changing of the Guard: Immune Checkpoint Inhibitors With and Without Chemotherapy as First Line Treatment for Metastatic Non-small Cell Lung Cancer

(2019) Jose M. Pacheco et al.   Frontiers in Oncology

Immunotherapy Associated Pulmonary Toxicity: Biology Behind Clinical and Radiological Features

(2019) Michele Porcu et al.   Cancers

Current Status and Future Direction of Immunotherapy in Urothelial Carcinoma

(2019) Michael Lattanzi et al.   Current Oncology Reports

Immune Checkpoint Inhibitors in Acute Myeloid Leukemia: Novel Combinations and Therapeutic Targets

(2019) Maximilian Stahl et al.   Current Oncology Reports

Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis

(2019) Prabhakaran Kumar et al.   SEMINARS IN CANCER BIOLOGY

Immunotherapy and targeted therapy combinations in metastatic breast cancer

(2019) Francisco J Esteva et al.   LANCET ONCOLOGY

PD-1/PD-L1 immune-checkpoint inhibitors in glioblastoma: A concise review

(2019) Mario Caccese et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes

(2019) Deborah B Doroshow et al.   CLINICAL CANCER RESEARCH

CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer

(2019) Laura M. McLane et al.   Annual Review of Immunology

Targeting the PD-1/PD-L1 Pathway in Renal Cell Carcinoma

(2019) Solène-Florence Kammerer-Jacquet et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

CD8+ T cell exhaustion

(2019) Makoto Kurachi   Seminars in Immunopathology

Lymphocyte Activation Gene-3 Maintains Mitochondrial and Metabolic Quiescence in Naive CD4+ T Cells

(2019) Dana M. Previte et al.   Cell Reports

Targeted Therapies and Immune-Checkpoint Inhibition in Head and Neck Squamous Cell Carcinoma: Where Do We Stand Today and Where to Go?

(2019) Jens von der Grün et al.   Cancers

The Integration of Radiotherapy With Immunotherapy for the Treatment of Non-Small Cell Lung Cancer

(2018) Eric C. Ko et al.   CLINICAL CANCER RESEARCH

CD103+Tumor-Resident CD8+T Cells Are Associated with Improved Survival in Immunotherapy-Naïve Melanoma Patients and Expand Significantly During Anti–PD-1 Treatment

(2018) Jarem Edwards et al.   CLINICAL CANCER RESEARCH

LAG-3 Inhibitory Receptor Expression Identifies Immunosuppressive Natural Regulatory Plasma Cells

(2018) Andreia C. Lino et al.   IMMUNITY

Lymphocyte-Activation Gene-3 Expression and Prognostic Value in Neoadjuvant-Treated Triple-Negative Breast Cancer

(2018) Yunxuan Wang et al.   Journal of Breast Cancer

DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer

(2018) Varun Sasidharan Nair et al.   Clinical Epigenetics

Soluble LAG3 acts as a potential prognostic marker of gastric cancer and its positive correlation with CD8+T cell frequency and secretion of IL-12 and INF-γ in peripheral blood

(2018) Na Li et al.   Cancer Biomarkers

TIGIT: a novel immunotherapy target moving from bench to bedside

(2018) Benjamin L. Solomon et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Generation of Fcabs targeting human and murine LAG-3 as building blocks for novel bispecific antibody therapeutics

(2018) Katy L. Everett et al.   METHODS

Immune-Related Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitors

(2018) Sabina Sandigursky et al.   Current Rheumatology Reports

Treatment-naïve HPV+ head and neck cancers display a T-cell-inflamed phenotype distinct from their HPV- counterparts that has implications for immunotherapy

(2018) Steven F. Gameiro et al.   OncoImmunology

Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3

(2018) Jun Wang et al.   CELL

Biological Consequences of Major Histocompatibility Class-II Expression by Tumor Cells in Cancer

(2018) Margaret L Axelrod et al.   CLINICAL CANCER RESEARCH

Class II MHC antigen processing in immune tolerance and inflammation

(2018) Mollie M. Jurewicz et al.   IMMUNOGENETICS

Targeting Adenosine Receptor Signaling in Cancer Immunotherapy

(2018) Kevin Sek et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial

(2018) Frank Stephen Hodi et al.   LANCET ONCOLOGY

LAG-3 inhibits the activation of CD4+ T cells that recognize stable pMHCII through its conformation-dependent recognition of pMHCII

(2018) Takumi Maruhashi et al.   NATURE IMMUNOLOGY

LAG-3: a very singular immune checkpoint

(2018) Yuan Lui et al.   NATURE IMMUNOLOGY

Endocrine and metabolic adverse effects of immune checkpoint inhibitors: an overview (what endocrinologists should know)

(2018) R. M. Ruggeri et al.   JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION

DNA methylation of immune checkpoints in the peripheral blood of breast and colorectal cancer patients

(2018) Asma A. Elashi et al.   OncoImmunology

TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy

(2017) William C. Dougall et al.   IMMUNOLOGICAL REVIEWS

The future of immune checkpoint cancer therapy after PD-1 and CTLA-4

(2017) Andrew W Hahn et al.   Immunotherapy

Mixed signature of activation and dysfunction allows human decidual CD8+T cells to provide both tolerance and immunity

(2017) Anita van der Zwan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition

(2017) Carlos R. Gil Del Alcazar et al.   Cancer Discovery

Immune Checkpoint Molecules on Tumor-Infiltrating Lymphocytes and Their Association with Tertiary Lymphoid Structures in Human Breast Cancer

(2017) Cinzia Solinas et al.   Frontiers in Immunology

Galectin 3 as a guardian of the tumor microenvironment

(2016) Peter P. Ruvolo   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation

(2016) Ana C. Anderson et al.   IMMUNITY

Pathological  -synuclein transmission initiated by binding lymphocyte-activation gene 3

(2016) X. Mao et al.   SCIENCE

Gut environment-induced intraepithelial autoreactive CD4+ T cells suppress central nervous system autoimmunity via LAG-3

(2016) Atsushi Kadowaki et al.   Nature Communications

Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer

(2016) Ruea-Yea Huang et al.   OncoImmunology

B-cell precursor acute lymphoblastic leukemia and stromal cells communicate through Galectin-3

(2015) Fei Fei et al.   Oncotarget

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014

(2014) R. Salgado et al.   ANNALS OF ONCOLOGY

LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses

(2014) F. Xu et al.   CANCER RESEARCH

Regulatory T Cells Inhibit Dendritic Cells by Lymphocyte Activation Gene-3 Engagement of MHC Class II

(2014) Bitao Liang et al.   JOURNAL OF IMMUNOLOGY

Trafficking of LAG-3 to the Surface on Activated T Cells via Its Cytoplasmic Domain and Protein Kinase C Signaling

(2014) Joonbeom Bae et al.   JOURNAL OF IMMUNOLOGY

MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial

(2014) Emanuela Romano et al.   Journal of Translational Medicine

The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints

(2014) Nicolas J. Llosa et al.   Cancer Discovery

Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients

(2013) H-B Jie et al.   BRITISH JOURNAL OF CANCER

Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells

(2013) Nicola Gagliani et al.   NATURE MEDICINE

A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma

(2012) Andrea Wang-Gillam et al.   INVESTIGATIONAL NEW DRUGS

Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape

(2011) S.-R. Woo et al.   CANCER RESEARCH

PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice

(2011) Taku Okazaki et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Therapeutic blockade of PD-L1 and LAG-3 rapidly clears established blood-stage Plasmodium infection

(2011) Noah S Butler et al.   NATURE IMMUNOLOGY

LAG-3 Expression Defines a Subset of CD4+CD25highFoxp3+ Regulatory T Cells That Are Expanded at Tumor Sites

(2010) C. Camisaschi et al.   JOURNAL OF IMMUNOLOGY

High Expression of Lymphocyte-Activation Gene 3 (LAG3) in Chronic Lymphocytic Leukemia Cells Is Associated with Unmutated Immunoglobulin Variable Heavy Chain Region (IGHV) Gene and Reduced Treatment-Free Survival

(2010) Jana Kotaskova et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Tumor-infiltrating NY-ESO-1–specific CD8+T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer

(2010) Junko Matsuzaki et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A Phase I Pharmacokinetic and Biological Correlative Study of IMP321, a Novel MHC Class II Agonist, in Patients with Advanced Renal Cell Carcinoma

(2009) C. Brignone et al.   CLINICAL CANCER RESEARCH

LAG-3 Regulates Plasmacytoid Dendritic Cell Homeostasis

(2009) C. J. Workman et al.   JOURNAL OF IMMUNOLOGY

Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection

(2008) Shawn D Blackburn et al.   NATURE IMMUNOLOGY